If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.


March 4, 2024 Cover

Volume 102, Issue 7

Cleantech start-ups vie for a piece of the PFAS destruction market

Full Article
Volume 102 | Issue 7

All Issues

Quote of the Week

“Our mission is to end PFAS, not to beat the other guys who are ending PFAS.”

Nigel Sharp, CEO and cofounder, Aquagga

  • US Defense Department funds chemical capacity building

    $192.5 million will help replace critical raw materials currently sourced abroad

  • Dispatch from the lab of the future

    The Society for Laboratory Automation and Screening’s annual conference offers a glimpse into labs staffed by robots

  • Indiana punts on PFAS bill

    Proposed law to narrow the definition of PFAS now floats in legislative limbo

image name
Drug Discovery

An antibiotic built for better binding

Cresomycin’s conformationally restricted structure makes a tight fit with bacterial ribosomes and pushes away methyl groups that can confer resistance